Groups | Mortalitya | Survival rate (%)b | B/B ratiosc | Histopathological BF lesion scoresd | Protectione (%) | IBDV in BTf (TCID50)/g | IBDV in NSg (TCID50)/mL | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | 5 | |||||||
Control unchallenged | 0/32 | 100 | 7.31 ± 0.343 | 32 | 0 | 0 | 0 | 0 | 0 | N/A | – | – |
Mock | 32/32 | 0 | 1.32 ± 0.277 | 0 | 0 | 0 | 2 | 8 | 22 | 0 | 7.87 × 108 | 4.66 × 104 |
chIL-7 | 30/32 | 6 | 2.47 ± 0.438 | 0 | 0 | 0 | 7 | 7 | 18 | 0 | 2.54 × 108 | 0.87 × 104 |
IBDV vaccine | 7/32 | 78 | 5.85 ± 0.510 | 18 | 5 | 5 | 2 | 2 | 0 | 72 | 5.67 × 103 | 0.72 × 102 |
IBDV vaccine + chIL-7 (50 μg) | 6/32 | 81 | 6.21 ± 0.253 | 20 | 5 | 4 | 2 | 1 | 0 | 78 | 0.55 × 103 | 0.07 × 102 |
IBDV vaccine + chIL-7 (100 μg) | 3/32 | 91 | 6.52 ± 0.448 | 23 | 5 | 2 | 2 | 0 | 0 | 88 | 0.63 × 102 | – |
IBDV vaccine + chIL-7 (200 μg) | 1/32 | 97 | 7.12 ± 0.436 | 27 | 3 | 2 | 0 | 0 | 0 | 94 | 0.16 × 102 | – |